Patents by Inventor Gabriel Mbalaviele

Gabriel Mbalaviele has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fluorescent methods for the high-throughput quantification of tartrate-resistant acid phosphatase (TRAP)
    Publication number: 20040259184
    Abstract: Methods for quantifying tartrate-resistant acid phosphotase (TRAP) activity, or determining the distribution of TRAP in a tissue are provided. More specifically, the fluorescent assay of the present invention is useful for identifying or quantifying TRAP in isolated osteoclast cells or osteoclasts differentiated from RAW264.7 monocyte-macrophage cells.
    Type: Application
    Filed: May 7, 2004
    Publication date: December 23, 2004
    Applicant: Pharmacia Corporation
    Inventors: Lee Albee, Gabriel Mbalaviele
  • Regulation of hematopoietic stem cell differentiation by the use of human mesenchymal stem cells
    Patent number: 6255112
    Abstract: The invention relates to the induction of hematopoietic stem cells to differentiate into osteoclasts by culturing hematopoietic stem cells with human mesenchymal stem cells, and, in a preferred embodiment, using no exogenous cytokines. Differentiation of the mesenchymal stem cells into osteoblasts inhibited the differentiation of hematopoietic stem cells into osteoclasts. In addition, hematopoietic stem cells can be genetically engineered to carry genes of interest particularly for the expression of physiologically active proteins. In the presence of mesenchymal stem cells, the transduced cells carry the new genetic material and express gene products that can be used to modulate bone resorption.
    Type: Grant
    Filed: June 8, 1999
    Date of Patent: July 3, 2001
    Assignee: Osiris Therapeutics, Inc.
    Inventors: Mark A. Thiede, Gabriel Mbalaviele
  • Inhibition of osteoclastogenesis
    Patent number: 6239157
    Abstract: A method for inhibiting the differentiation of CD34+ cells into osteoclasts by treating the cells with a peroxisome proliferator-activated receptor-&ggr; agonist.
    Type: Grant
    Filed: September 10, 1999
    Date of Patent: May 29, 2001
    Assignee: Osiris Therapeutics, Inc.
    Inventor: Gabriel Mbalaviele
  • Vitro maintenance of hematopoietic stem cells
    Patent number: 6030836
    Abstract: The present invention is directed to human mesenchymal stem cells isolated from a tissue specimen, such as marrow cells, and to the method of co-culturing isolated mesenchymal stem cells and/or mesenchymal stem cell-derived adipocytes with hematopoietic progenitor cells such that the hematopoietic stem cells retain their phenotype.
    Type: Grant
    Filed: June 8, 1999
    Date of Patent: February 29, 2000
    Assignee: Osiris Therapeutics, Inc.
    Inventors: Mark A. Thiede, Mark F. Pittenger, Gabriel Mbalaviele